Skip to main content

Skip to Investors Navigation

Pipeline

VMT01/02

Overview

VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas. It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb-212 for alpha particle therapy.

Development

  • US Therapeutic Dose Finding Trial recruiting currently throughout the US -- https://clinicaltrials.gov/study/NCT05655312?term=vmt01
  • Fast Track Designation received September 2024
  • Preclinical data shows synergistic effect with Immune Checkpoint Inhibitors
  • VMT01/ICI combination cohort open for recruitment
  • Phase 1 imaging study at Mayo Clinic Rochester indicates feasibility of patient selection using [203Pb]VMT01 and [68Ga]VMT02

Companion Diagnostic

Dompanion Diagnostic: F-FDG

18F-FDG (Standard of Care)

Companion Diagnostic: VMT02

[68GA]VMT-02

Patient information:
Male, Asian, 33 years old
[68Ga]VMT02: 7 mCi injection, 45 min post-injection imaging

Clinical Collaborator

Xiaowei Ma, M.D., Ph.D.

Assoc. Prof. & Director, Department of Nuclear Med.
The Second Xiangya Hospital, Central South University, China